New CDK4/6 Strategies in HR+/HER2– Breast Cancer: Imlunestrant ± Abemaciclib and the Avutometinib Triplet
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 20, 2026. n Hormone receptor–positive, HER2-negative (HR+/HER2–) metastatic